Toll Group has announced the construction of a new, 10,000 sqm state-of-the-art healthcare facility at Tullamarine, near Melbourne, next to what will be one of its partners’ future manufacturing sites.
As a leading supply chain partner to CSL Seqirus, the facility is being custom built to support CSL Seqirus’ operations.
Toll notes by having its warehouse and DC next to what will be CSL Seqirus’s manufacturing site, it will bolster Toll’s tailored support for CSL Seqirus by handling both finished goods distribution and supplying raw materials and packaging to the CSL Seqirus manufacturing facility.
“We are proud to strengthen our partnership with CSL Seqirus and expand our footprint in the healthcare logistics sector,” says Perry Singh, President, Government & Defence at Toll.
“This new facility exemplifies our commitment to delivering high-quality, tailored supply chain solutions to meet the evolving needs of our customers.”
The new warehouse marks Toll’s commitment to providing comprehensive logistics solutions for the healthcare sector.
With operations commencing in Tullamarine, Toll aims to enhance efficiency and timeliness through just-in-time services. The collaboration between Toll and CSL Seqirus underscores a shared dedication to innovation and excellence in healthcare logistics.
In addition to the Tullamarine facility, in April 2023 Toll opened new warehouse in Richlands, Queensland, further demonstrating its dedication to enhancing healthcare logistics infrastructure across Australia.
“The facilities are part of Toll’s broader multi-million-dollar investment creating advanced warehouse management solutions to meet the changing dynamics in the healthcare sector, and providing customers with the logistical support they need,” adds Perry.
Toll’s facility will be situated adjacent to the soon-to-be-completed CSL Seqirus plant, a new world-class biotech manufacturing facility in Australia which will supply influenza vaccines to Australia and the rest of the world.
The state-of-the-art facility will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs – and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.
Toll’s warehouse and DC is due to commence operations in August 2024.
For more information on Toll Group, click here.